Human HLA-A*02:01&B2M&TERT (ILAKFLHWL) Monomer Protein
Catalog No: TERT-HP002
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Human HLA-A*02:01&B2M&TERT (ILAKFLHWL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and ILAKFLHWL peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &ILAKFLHWL).
Product Details
- Molecular Aliases
- TERT; ILAKFLHWL
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 50.60 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human HLA-A*02:01&B2M&TERT (ILAKFLHWL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&TERT (ILAKFLHWL) Monomer is greater than 95% as determined by SEC-HPLC.
Background
The human telomerase catalytic subunit human telomerase reverse transcriptase (hTERT) is expressed in many human cancer cells derived from multiple tissues, but infrequently in normal cells. Thus, hTERT is an attractive candidate target for tumor immunotherapy. hTERT:540–548 peptide (p540, ILAKFLHWL) has been identified as an effective HLA-A*0201-restricted T-cell epitope, an effective T-cell-based cancer treatment, including vaccines, against hTERT will likely require the identification of other MHC class I-restricted epitopes in this antigen.
References
- Huang G, Geng J, Wang R, Chen L. Identification of a new cytotoxic T-cell epitope p675 of human telomerase reverse transcriptase. Cancer Biother Radiopharm. 2012 Nov;27(9):600-5. doi: 10.1089/cbr.2012.1193. Epub 2012 Aug 23. PMID: 22917214.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.